Bronx Transthyretin Amyloid Cardiomyopathy Database

Montefiore Medicine Academic Health System

Status: Active, not recruiting

Conditions: Transthyretin Amyloid Cardiomyopathy; Transthyretin Cardiac Amyloidosis

Treatments: Diagnostic Test: 99mTc-pyrophosphate Single Photon Emission Computed Tomography

Study type: Observational

Funder types: Other

Identifiers

NCT06257485

2023-15264

Details and patient eligibility

About

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.

Enrollment: 476 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All adult patients referred for PYP SPECT at Montefiore Medical Center between 2014 and 2023

Exclusion criteria

• Did not have a transthoracic echocardiogram in our medical records

Trial design

476 participants in 1 patient group

Patients referred for 99mTc-pyrophosphate Single Photon Emission Computed Tomography

Description:

Patients with suspected transthyretin cardiac amyloidosis referred for 99mTc-pyrophosphate Single Photon Emission Computed Tomography

Treatment:

Diagnostic Test: 99mTc-pyrophosphate Single Photon Emission Computed Tomography